Biodistribution and radiation dosimetry of ¹²⁴I-mIBG in adult patients with neural crest tumours and extrapolation to paediatric models.

"Disclosures Walter Jentzen received research funding from Siemens Healthineers. Ken Herrmann reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, personal fees from Aktis Oncology, personal fees from Theragnostics, personal fees from Pharma15, personal fees from Debiopharm, personal fees from AstraZeneca, and personal fees from Janssen outside of the submitted work. Wolfgang P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Calyx (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker), Telix (speaker), GE (speaker), and Eczacıbaşı Monrol (speaker) outside of the submitted work. David Kersting reports a research grant from Pfizer and support by the German Research Foundation (DFG) outside of the submitted work. The other authors have nothing to declare. Declarations Competing interestsThe authors declare that they have no competing interests. Competing interests The authors declare that they have no competing interests."

"Funding Open Access funding enabled and organized by Projekt DEAL."